EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Clinical Characteristics and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement

Daniel Hagemeyer, Anas Merdad, Laura Villegas Sierra, Andrea Ruberti, Faraj Kargoli, Marine Bouchat, Mauro Boiago, Aris Moschovitis, Djeven P Deva, Lukas Stolz, Geraldine Ong, Mark D Peterson und 8 weitere

JACC: Cardiovascular Interventions · 2024

DOI: 10.1016/j.jcin.2023.12.016 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Daniel Hagemeyer und 19 weiteren Autor:innen. Beteiligte Einrichtung: Structural Heart Program, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Tricuspid Valve Insufficiency, Heart Failure. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transcatheter tricuspid valve replacement (TTVR) abolishes tricuspid regurgitation (TR) and has emerged as a definitive treatment for TR. OBJECTIVES: The purpose of this multicenter, observational study was to determine the clinical characteristics and short-term outcomes of patients with TR screened for TTVR. METHODS: Patients underwent TTVR screening at 7 centers on a compassionate-use basis. The primary endpoints were NYHA functional class and TR grade at 30-day follow-up. Secondary endpoints included all-cause mortality, heart failure hospitalization, technical success, and reasons for TTVR screening failure. RESULTS: A total of 149 patients (median age 79 years [Q1-Q3: 72-84 years], 54% women) underwent TTVR screening. The TTVR screening failure rate was 74%, mainly related to large tricuspid annular diameter. Patients undergoing TTVR (n = 38) had significant functional improvements (NYHA functional class I or II from 21% to 68%; P < 0.001), with TR ≤1+ in 97% at 30-day follow-up (P < 0.001 from baseline). Technical success was achieved in 91%, with no intraprocedural mortality or conversion to surgery. At 30-day follow-up, mortality was 8%, heart failure hospitalization 5%, major bleeding 18%, and reintervention 9%. Patients who failed screening for TTVR and subsequently underwent "bailout" transcatheter edge-to-edge repair (n = 26) had favorable outcomes (NYHA functional class I or II from 27% to 58%; P < 0.001), with TR ≤1+ in 43% at 30-day follow-up (P < 0.001 from baseline). CONCLUSIONS: This first real-world report of TTVR screening demonstrated a high screening failure rate, mainly related to large tricuspid annular diameter. Patients undergoing TTVR had superior TR reduction and symptom alleviation compared with bailout tricuspid transcatheter edge-to-edge repair, at the cost of greater procedural complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve Prosthesis ImplantationTricuspid Valve InsufficiencyHeart FailureHumansFemaleAgedMaleTricuspid ValveHemodynamicsCardiac CatheterizationTreatment OutcomeRecovery of FunctionTime FactorsSeverity of Illness IndexRegistries

Stichwörter der Autor:innen

transcatheter edge-to-edge repairtranscatheter tricuspid valve replacementtricuspid regurgitation

Autor:innen und Institutionen

  • Structural Heart Program, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany; German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany.
  • Division of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Medico-Surgical Department (Valvulopathies, Cardiac Surgery, Adult Interventional Cardiology), Hôpital Cardiologique de Haut-Lévèque, Bordeaux University Hospital, Bordeaux, France.
  • Groupe Cardio-Vasculaire lnterventionnel, Cinique Pasteur, Toulouse, France.

Zitieren

APA

Hagemeyer, D., Merdad, A., Sierra, L. V., Ruberti, A., Kargoli, F., Bouchat, M., Boiago, M., Moschovitis, A., Deva, D. P., Stolz, L., Ong, G., Peterson, M. D., Piazza, N., Taramasso, M., Dumonteil, N., Modine, T., Latib, A., Praz, F., Hausleiter, J., & Fam, N. P. (2024). Clinical Characteristics and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2023.12.016

Vancouver

Hagemeyer D, Merdad A, Sierra LV, Ruberti A, Kargoli F, Bouchat M, et al. Clinical Characteristics and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2023.12.016

BibTeX
@article{Hagemeyer2024,
  author = {Hagemeyer, Daniel and Merdad, Anas and Sierra, Laura Villegas and Ruberti, Andrea and Kargoli, Faraj and Bouchat, Marine and Boiago, Mauro and Moschovitis, Aris and Deva, Djeven P and Stolz, Lukas and Ong, Geraldine and Peterson, Mark D and Piazza, Nicolo and Taramasso, Maurizio and Dumonteil, Nicolas and Modine, Thomas and Latib, Azeem and Praz, Fabien and Hausleiter, Jörg and Fam, Neil P},
  title = {Clinical Characteristics and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  doi = {10.1016/j.jcin.2023.12.016}
}
Kostenlos starten →